Asceftra Injection

Description

Asceftra Injection

Fight against complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia.

ASCEFTRA
CEFEPIME 1G injection

CEFEPIME FOR INJECTION USP
ASCEFTRA INJECTION
For I.M./I.V. use
Composition: Cefepime 1g + 10 ml Diluent
S Star

RECOMMENDED DOSAGE

INTRAMUSCULAR, INTRAVENOUS

Adult:
Dose and route of administration may vary according to the severity of the infection, renal function, and general condition of the patient.

For complicated and uncomplicated cases:

• Mild to moderate cases: 0.5–1 g 12 hourly via IV injection or infusion over at least 30 minutes or IM injection.

• Severe cases: 2 g 12 hourly via IV injection or infusion over at least 30 minutes; may be increased to 2 g 8 hourly for very severe infections.

• Max: 2 g 8 hourly.

• Usual treatment duration: 7–10 days.
  Dosage recommendations may vary among countries and individual products (refer to detailed product or local treatment guidelines).

Child:

• >2 months ≤40 kg: 50 mg/kg 12 hourly for 10 days; may increase frequency to 8 hourly in more severe cases.

• >40 kg: Same as adult dose.
  Dosage recommendations may vary among countries and individual products (refer to detailed product or local treatment guidelines).

Pediatric Patients

(2 months up to 16 years)
The maximum dose for pediatric patients should not exceed the recommended adult dose.

The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered q12h (50 mg/kg/dose, q8h for febrile neutropenic patients) for durations as given on the table.

SUPERIOR BENEFITS OF ASCEFTRA

1. Effective against P. aeruginosa

2. Has activity against carbapenem-resistant organisms

3. Effective against extended-spectrum beta-lactamase-producing strains of bacteria

4. Crosses the blood-brain barrier, hence very effective in cases of meningitis

5. Effective against sturdy organisms & spore-forming bacteria like Staph. aureus etc.

6. Generally minimal side effects & highly decreased adverse events

7. Reduces cost & added risks of antibiotic combinations & adverse drug-drug interactions/reactions

8. Covers more gram-positive & gram-negative organisms than 3rd-generation cephalosporins